SAILIFEBSESai Life Sciences LtdHighNeutral
Announced Thu, 14 May · 23:09 IST

Audited Financial Results for the year ended 31 March, 2026

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF

SAILIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.8%1-day move
₹1119.00
prior close
₹1048.30
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-5.2-5.6-6.8-8.0+0.8+0.8+2.7+1.7-1.2+1.7+6.1+7.5+13.0
Up moveDown movePending
AI summary

Sai Life Sciences reported strong full-year results with standalone revenue growing 31% to Rs 21,532 million from Rs 16,420 million. Profit after tax nearly doubled to Rs 3,415 million from Rs 1,735 million, representing 97% PAT growth. Basic EPS improved to Rs 16.27 from Rs 9.00. Consolidated revenue stood at Rs 21,925 million with PAT of Rs 3,489 million. The company had exceptional items of Rs 80.01 million related to Labour Code implementation. Operating cash flow remained strong at Rs 4,953 million. Auditors Deloitte Haskins & Sells LLP issued an unmodified opinion on the annual results. The company completed its IPO in December 2024 and deployed Rs 9,099 million of proceeds primarily for debt repayment.

Likely market impact

The results show robust growth with PAT nearly doubling year-on-year, indicating strong operational performance and margin expansion. The clean audit opinion without any qualifications supports financial reliability. Shareholders can expect positive sentiment given the exceptional revenue and profit growth.